AMSTERDAM / LONDON (IT BOLTWISE) – Dutch biotech company arGEN-X has significantly increased its sales and profits, but this only had a temporary positive impact on its share price. Despite its inclusion in the EuroStoxx 50 and the positive response to the progress in drug development, the EURONEXT share fell by 2.43 percent. Analysts praise the company’s solid results and ambitious goals for 2030.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
The Dutch biotech company arGEN-X recently published impressive financial figures, but they were not enough to sustainably support the share price. Despite an increase in sales to over 1.1 billion US dollars and a quadrupling of profits to 344 million dollars, the share on EURONEXT recorded a decline of 2.43 percent. This development is surprising since arGEN-X was recently included in the EuroStoxx 50, which is usually considered a positive signal for investors.
The company’s main source of revenue is the drug Vyvgart, which is used to treat the autoimmune disease myasthenia gravis. Vyvgart, which contains the active ingredient efgartigimod alfa, is considered to be first in its class and was also recently approved for the treatment of chronic inflammatory demyelinating polyneuropathy. This expansion of the scope shows the potential of the drug, which is already being tested in several other indications.
Analysts like Bernstein’s Justin Smith praise arGEN-X’s financial results and highlight the company’s ambitious goals. By 2030, arGEN-X plans to receive approvals for ten different applications and treat 50,000 patients with its drugs. These long-term plans underscore the company’s commitment to further expand its market position and explore new therapeutic opportunities.
Although specific sales or profit targets for the current year were not mentioned, arGEN-X is confident that the ongoing studies and the planned market approvals will continue to drive growth. The biotech industry is eagerly watching to see how developments in arGEN-X will impact the market, particularly given the competition and regulatory challenges that exist in the sector.
*Order an Amazon credit card with no annual fee with a credit limit of 2,000 euros! a‿z
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “arGEN-X: Shares fall despite jump in profits”.
The post Despite a jump in profits, the stock is falling appeared first on Veritas News.
